↓ Skip to main content

Dove Medical Press

Article Metrics

Pazopanib for the treatment of soft-tissue sarcoma

Overview of attention for article published in Clinical Pharmacology : Advances and Applications, October 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
26 Mendeley
Title
Pazopanib for the treatment of soft-tissue sarcoma
Published in
Clinical Pharmacology : Advances and Applications, October 2012
DOI 10.2147/cpaa.s33195
Pubmed ID
Authors

Isabelle Ray-Coquard, Cassier, Derbel, Dufresne, Meeus, Thiesse, Ranchere-Vince, Blay, Heudel

Abstract

Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 4%
Unknown 25 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 15%
Student > Master 4 15%
Professor > Associate Professor 3 12%
Student > Bachelor 3 12%
Student > Ph. D. Student 2 8%
Other 6 23%
Unknown 4 15%
Readers by discipline Count As %
Medicine and Dentistry 14 54%
Agricultural and Biological Sciences 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Biochemistry, Genetics and Molecular Biology 1 4%
Chemistry 1 4%
Other 0 0%
Unknown 5 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2012.
All research outputs
#2,494,499
of 5,036,908 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#32
of 73 outputs
Outputs of similar age
#37,276
of 84,772 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#2
of 2 outputs
Altmetric has tracked 5,036,908 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 73 research outputs from this source. They receive a mean Attention Score of 1.9. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 84,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.